A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Month Year

Jul 27, 2016

CYTOKINETICS AND ASTELLAS ANNOUNCE OPTION RIGHT FOR TIRASEMTIV AND EXPANSION OF GLOBAL COLLABORATION FOR CK-2127107 IN ALS

Cytokinetics to Receive $65 Million in Upfront Payments and $30 Million in Additional Sponsored R&D; Potential for More than $100 Million in Payments Associated with the Exercise of the Option

SOUTH SAN FRANCISCO, Calif. and TOKYO, Japan, July 27, 2016 – Cytokinetics, Inc. (Nasdaq: CYTK, “Cytokinetics”) and Astellas Pharma Inc. (TSE: 4503, “Astellas”) today announced that...

Read more about CYTOKINETICS AND ASTELLAS ANNOUNCE OPTION RIGHT FOR TIRASEMTIV AND EXPANSION OF GLOBAL COLLABORATION FOR CK-2127107 IN ALS
Jul 25, 2016

Astellas and FibroGen Announce First Patient Treated in Phase 3 Studies and Positive Phase 2 Results of Roxadustat in Patients with Chronic Kidney Disease in Japan

Read more about Astellas and FibroGen Announce First Patient Treated in Phase 3 Studies and Positive Phase 2 Results of Roxadustat in Patients with Chronic Kidney Disease in Japan
Jul 6, 2016

Astellas Named to FTSE4Good Sustainability Index for the Fifth Consecutive Year

Tokyo, July 6, 2016 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it has been selected for the fifth consecutive year to be included in the...

Read more about Astellas Named to FTSE4Good Sustainability Index for the Fifth Consecutive Year
Jun 23, 2016

The Institute of Medical Science, the University of Tokyo and Astellas Enter into a New Collaborative Development Agreement for Rice-Based Oral Vaccine

Tokyo, June 23, 2016 - the Institute of Medical Science, the University of Tokyo (Tokyo, Dean: Yoshinori Murakami, “IMSUT”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko...

Read more about The Institute of Medical Science, the University of Tokyo and Astellas Enter into a New Collaborative Development Agreement for Rice-Based Oral Vaccine
Jun 2, 2016

ASTELLAS AND MEDIVATION INITIATE PHASE III TRIAL OF ENZALUTAMIDE IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER

Read more about ASTELLAS AND MEDIVATION INITIATE PHASE III TRIAL OF ENZALUTAMIDE IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER

Show per page

Discover more

Return to media homepage

Follow us

Subscribe to news alerts